Alpha 2.0
Login Register
» Authors » Masao Toyoda

Masao Toyoda

Explore the profile of Masao Toyoda including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 117
Citations 1110
Followers 0
Related Specialties
General Medicine
Endocrinology
Nephrology
Top 10 Co-Authors
Daisuke Suzuki
Moritsugu Kimura
Tomoya Umezono
Masafumi Fukagawa
Masaaki Miyauchi
Takashi Murata
Nobumichi Saito
Nobuo Hatori
Kazuo Kobayashi
Kouichi Tamura
Published In
Tokai J Exp Clin Med
Intern Med
J Diabetes Investig
J Diabetes Res
Clin Exp Nephrol
Affiliations
Soon will be listed here.
Recent Articles
1.
The Relationship Between the Percent Coefficient of Variation of Sensor Glucose Levels and the Risk of Severe Hypoglycemia or Non-Severe Hypoglycemia in Patients With Type 1 Diabetes: Post Hoc Analysis of the ISCHIA Study
Murata T, Matsuhisa M, Kuroda A, Toyoda M, Hirota Y, Ogura M, et al.
J Diabetes Sci Technol . 2025 Feb; :19322968251318756. PMID: 39960254
Background: The relationship between the percent coefficient of variation (%CV) and the risk of severe hypoglycemia (SH) or non-severe hypoglycemia (NSH) in patients with type 1 diabetes (T1D) remains to...
2.
Cost-effective analysis focused on hypoglycemia of intermittent-scanning continuous glucose monitoring in type 1 diabetes adults: a ISCHIA randomized clinical trial
Sakane N, Matsuhisa M, Kuroda A, Miura J, Hirota Y, Kato K, et al.
Diabetol Int . 2025 Jan; 16(1):78-85. PMID: 39877450
Background: This study aimed to compare the economic value of intermittent-scanning continuous glucose monitoring (isCGM) with self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes (T1D). Methods: Participants...
3.
Diurnal variation in the association between the scan frequency of isCGM and CGM metrics: post hoc analysis of the ISCHIA study
Meguro S, Sakane N, Hosoda K, Hirota Y, Itoh A, Kato K, et al.
Diabetol Int . 2024 Oct; 15(4):828-836. PMID: 39469556
Background And Aims: To investigate the association between the frequency of intermittent-scanning continuous glucose monitoring (isCGM) and diurnal variation of time in range (TIR), time above range (TAR), and time...
4.
Difference in the accuracy of the third-generation algorithm and the first-generation algorithm of FreeStyle Libre continuous glucose monitoring device
Murata T, Sakane N, Hirota Y, Toyoda M, Matsuhisa M, Kuroda A, et al.
J Med Invest . 2024 Oct; 71(3.4):225-231. PMID: 39462556
Background: FreeStyle Libre uses the algorithm to calculate the sensor glucose (SG) levels. The manufacturer announced that they had changed the algorithm from the first generation (Gen. 1) to the...
5.
A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope
Miyamoto S, Heerspink H, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, et al.
Kidney Int . 2024 Aug; 106(5):972-984. PMID: 39216659
Demonstrating drug efficacy in slowing kidney disease progression requires large clinical trials when targeting participants with an early stage of chronic kidney disease (CKD). In this randomized, parallel-group, open-labeled trial...
6.
Study of the Effects of Deuterium-Depleted Water on the Expression of GLUT4 and Insulin Resistance in the Muscle Cell Line C2C12
Kondo M, Sawada K, Matsuda Y, Abe M, Sanechika N, Takanashi Y, et al.
Biomedicines . 2024 Aug; 12(8). PMID: 39200235
Deuterium-depleted water (DDW) is used in the treatment of many diseases, including cancer and diabetes. To detect the effect of DDW on gene expression and activation of the insulin-responsive transporter...
7.
Comparison of Points in Range Measured by the Self-monitoring of Blood Glucose and Time in Range Measured by the Continuous Glucose Monitoring
Mori Y, Sakane N, Kimura M, Murata T, Toyoda M
Tokai J Exp Clin Med . 2024 Aug; 49(3):105-109. PMID: 39182177
Objective: Usage of time in range (TIR), measured by continuous glucose monitoring (CGM), has become common as a new index of glycemic control. Therefore, we compared points in range (PIR),...
8.
Predictors of the effectiveness of isCGM usage in adults with type 1 diabetes mellitus: post-hoc analysis of the ISCHIA study
Murata T, Hirota Y, Hosoda K, Kato K, Kouyama K, Kouyama R, et al.
Diabetol Int . 2024 Aug; 15(3):400-405. PMID: 39101179
Aim: The Effect of Intermittent-Scanning Continuous Glucose Monitoring to Glycemic Control Including Hypoglycemia and Quality of Life of Patients with Type 1 Diabetes Mellitus (ISCHIA) study was a randomized, crossover...
9.
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease
Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, et al.
Diabetes Obes Metab . 2024 May; 26(8):3248-3260. PMID: 38764356
Aim: To conduct a post hoc subgroup analysis of patients with type 2 diabetes (T2D) from the RECAP study, who were treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor and glucagon-like peptide...
10.
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, et al.
Front Pharmacol . 2024 Apr; 15:1358573. PMID: 38601470
Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. Combination therapy with SGLT2i and GLP1Ra is...